Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruitingRare disease

Study on the Effectiveness and Safety of Iptacopan for Patients with Primary IgA Nephropathy

Verified siteInvestigational
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying a kidney disease called IgA Nephropathy, which affects the kidneys' ability to filter waste from the blood. The study is testing a new treatment called Iptacopan, also known by its code name LNP023. This medication is taken in the form of hard gelatin capsules. The purpose of the study is to evaluate how effective and safe Iptacopan is for patients with IgA Nephropathy.

Participants in the study will be randomly assigned to receive either Iptacopan or a placebo, which looks like the medication but does not contain the active ingredient. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo. This helps ensure that the results are not biased. The study will last for a total of 24 months, with an interim analysis at 9 months to assess the initial effects of the treatment.

Throughout the study, participants will have regular check-ups to monitor their health and the progression of their kidney disease. The main focus will be on measuring protein levels in the urine, which is an indicator of kidney function, and observing any changes in kidney function over time. The study aims to determine if Iptacopan can reduce protein levels in the urine and slow down the progression of IgA Nephropathy compared to the placebo. Participants will also be monitored for any side effects or adverse reactions to the treatment.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, the patient will be randomly assigned to receive either the study medication, iptacopan, or a placebo. The placebo is a capsule that looks like the medication but does not contain the active substance.

    The study is designed to be double-blind, meaning neither the patient nor the researchers will know which treatment the patient is receiving.

  2. Step 2

    Medication administration

    The patient will take the assigned capsule orally. The dosage and frequency will be determined by the study protocol, which is not specified in the provided data.

    The duration of the medication administration will be up to 24 months, depending on the patient's progress and the study's requirements.

  3. Step 3

    Monitoring and assessments

    Throughout the study, the patient's health will be monitored regularly. This includes collecting urine samples to measure protein levels and conducting blood tests to assess kidney function.

    The primary goal is to evaluate the reduction of protein in the urine at 9 months and to monitor the progression of kidney function over 24 months.

  4. Step 4

    Safety evaluations

    Safety assessments will be conducted to monitor any adverse effects or serious health events. This includes checking vital signs and laboratory parameters.

    These evaluations will occur from the start of the study until 9 months and continue until the end of the study.

  5. Step 5

    Completion of the study

    The study is expected to conclude by September 2025. At the end of the study, the collected data will be analyzed to determine the effectiveness and safety of the medication.

    The final analysis will focus on the long-term impact on kidney function and the overall health outcomes for the patient.

Who can join the trial?

7 criteria

  • Must be a male or female who is 18 years of age or older.
  • Must have a confirmed diagnosis of **IgA Nephropathy** through a kidney biopsy.
  • Must have a certain level of kidney function, measured by **eGFR** (a test that shows how well your kidneys are working). The required eGFR levels depend on the time since the biopsy and the amount of kidney damage.
  • Must have **proteinuria** (a condition where there is too much protein in the urine) due to IgA Nephropathy, with specific levels measured during screening and at the start of the study.
  • Must be vaccinated against certain infections like **Neisseria meningitidis** and **Streptococcus pneumoniae** before starting the study treatment. If not previously vaccinated, the vaccine should be given at least 2 weeks before starting the study drug. If the study drug needs to start earlier, antibiotics should be used to prevent infection.
  • If not previously vaccinated, should receive a vaccine against **Haemophilus influenzae** infections, if available, at least 2 weeks before starting the study drug.
  • Must have been on supportive care, including a stable dose of medications like **ACE inhibitors** or **ARBs** (medications that help control blood pressure and protect the kidneys) for about 90 days before starting the study drug. If taking other medications for IgA Nephropathy, those doses should also be stable for about 90 days before starting the study treatment.

Who cannot join the trial?

9 criteria

  • Patients who are not diagnosed with IgA Nephropathy, a kidney condition.
  • Patients who are younger than 18 years old or older than 75 years old.
  • Patients who are not able to provide a 24-hour urine collection for testing.
  • Patients who have other serious health conditions that might interfere with the study.
  • Patients who are pregnant or breastfeeding.
  • Patients who are participating in another clinical trial at the same time.
  • Patients who have a history of drug or alcohol abuse.
  • Patients who have had a kidney transplant.
  • Patients who are unable to follow the study procedures or attend study visits.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

LNP023 is a medication being studied for its potential to help patients with primary IgA nephropathy, a kidney disease. The trial aims to see if LNP023 can reduce the amount of protein in the urine, which is a sign of kidney damage, and slow down the progression of the disease over time.

What is already known about the treatment

LNP023 – This medication is administered orally and is currently being studied in clinical trials for its effectiveness in treating IgA Nephropathy, a kidney condition. It is in the phase III stage of clinical trials, which means it is being tested for safety and efficacy in a larger group of patients. The main therapeutic indication for LNP023 is to reduce proteinuria, which is the presence of excess protein in the urine, and to slow the progression of kidney damage in patients with IgA Nephropathy. At the molecular level, LNP023 works by inhibiting a specific protein in the immune system that contributes to kidney inflammation and damage. It is classified pharmacologically as a complement inhibitor, targeting the complement system involved in immune responses.

Investigated diseases

IgA Nephropathy – IgA Nephropathy is a kidney disease that occurs when an antibody called immunoglobulin A (IgA) builds up in the kidneys, leading to inflammation. This inflammation can affect the kidneys' ability to filter waste from the blood. Over time, the disease can cause the kidneys to leak blood and protein into the urine. The progression of IgA Nephropathy can vary, with some individuals experiencing slow progression over many years, while others may see a more rapid decline in kidney function. Symptoms may include blood in the urine, swelling in the hands and feet, and high blood pressure. The exact cause of IgA Nephropathy is not well understood, but it is believed to involve genetic and environmental factors.
Trial detailsLast updated 7 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2024-511067-29-00Protocol codeCLNP023A2301Estimated enrolment514 patientsSponsorNovartis Pharma AG

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.